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,CHAPTER I
INTRODUCTION
1.1. Background
Reports coming from around the globe show an increase in the incidence of
emerging diseases such as EOOla hemorrhagic fever, AIDS, Japanese encephalitis. West
Nile virus encephalitis, tuberculosis, new variant Creutzfeld-Jakob disease, syphilis, viral
hepatitis, diphtheria, measles. meningococcal disease, and others [46, 55, 89]. Despite
armed with recent medical advances, these emerging diseases present a significant threat
to humanity and posses a potential economic loss. Therefore, a bener understanding of
pathogens and the diseases they cause is pertinent in the development of preventive
measures.
A pathogen is defmed as any organism capable of invading another living
organism, resulting in the development of disease in the host [4]. Pathogenicity is the
ability of microorganisms to cause disease, while virulence is a measure of pathogens'
ability to inflict severe disease [4]. Both pathogenicity and virulence are multi-factorial.
Factors include the interactions between the host and the pathogen as well as other
environmental factors [4]. Characteristics of influenza virus such as rapid mutation rate.
antigenic shift and drift. airborne transmission, and the ability of avian viruses to directly
infect humans defme this virus as a significant emerging infectious agent.
Influenza is a highly contagious disease caused by influenza irus infection.
Spread from person to person and within a community is very rapid, resulting in 20 000
deaths annually in the U.S. [11]. Fever ranging from 38 to 40 °C, peaks ithin 24 hours
of onset that lasts from one to five days is a common symptom in influenza. Other
symptoms include chills, nausea, abdominal pain, diarrhea, a generalized feeling of
weakness, muscle pain, and soreness of the respiratory tract [67]. Symptoms elicited by
influenza virus infection are attributed to the release of cytokines by the immune
response towards the virus [22, 33,81].
Influenza viruses are divided into three types A, B, and C, based on their
antigenicity. Influenza A virus, the most pathogenic of the three types is further divided
into 15 HA and 9 NA subtypes [19]. All of the influenza A virus subtypes are found in
waterfowl [91,93). Two highly immunogenic viral surface proteins, viral hemagglutinin
(HA) and neuraminidase (NA), have been associated with virus pathogenicity. The HA
of highly pathogenic avian influenza. virus (H7N7 and H5N2) has been implicated in the
pathogenicity of these viruses [2, 4 I]. In addition, the internal NP gene, which plays a
role in host range, has been implicated in contributing to disease development.
Surveillance of influenza virus (and influenza) by the World Health Organization
(WHO), and by the Centers for Disease Control and Prevention (CDC). is a global effort
to improve disease prevention and for vaccine formulation. A vaccine is available for
influenza prevention. This vaccine, administered annually, contains two inactivated
viruses of currently circulating influenza A viruses (subtypes HINt and H3N2) and one
circulating influenza B virus. This vaccine provides only a short-term protection. and
does not provide protection against future epidemic or pandemic influenza virus due to
2
antigenic drift and antigenic shift, respectively.
Despite the concern over a new pandemic, the molecular basis of influenza virus
pathogenicity is not well understood. A better understanding of molecular factors
involved in virus pathogenicity will assist in development of a better protection against
influenza.
1.2. Research summary
1.2.1. Study problem
Why have only three (HI, H2, and ill) out of fifteen HA subtypes been
circulating in humans? Why are some influenza viruses, such as H7N7. H5N2 and
H5N I, but not other subtypes highly pathogenic in chickens? Is the hemagglutinin solely
responsible for viral pathogenicity? If so, what is the mechanism?
1.2.2. Study hypothesis and speculations
The level of cytokine release, such as IL-6, has been shown to correlate with the
severity of symptoms; i.e., a higher level of IL-6 results in a higher fever [22, 33, 81 ];.
Furthermore, infection by influenza Band C viruses usually results in milder disease with
less severe symptoms, than influenza A viruses. Therefore, there appears to be a
correlation between pathogenicity and cytokine level. I hypothesize that. using an in
vitro lymphocytic culture a more pathogenic influenza virus would induce a higher level
ofcytokines. I postulate that HA is an important factor in determining pathogenicity, and
that the increased pathogenicity is a result of increased induction of cytokines. This can
be assayed by the in vitro lymphocyte model. By using different influenza viruses, I will
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be able to test this hypothesis.
1.2.3. Objectives
Since more pathogenic virus induces a higher level of cytokines in th host, the
fIrst objective will be to establish an in vitro model (using a human Jurkat T cell line and
human umbilical cord blood lymphocytes) to mimic virus infection in vivo. The in vitro
lymphocyte culture will be infected with influenza virus; the induction of cytokines will
be measured both at the transcriptional and at the translational level. The second
objective will be to determine if the levels of cytokine induced in this model using
different influenza viruses correlate with their pathogenicity in vivo.
1.2.4. Limitations
In mammals including humans, the site of influenza virus infection is the upper
respiratory tract. The cytokines are released from tissue dendritic cells. This results in
development of immune response as well as common influenza symptoms. This in vitro
lymphocyte model may not be a perfect model, as the ratio of dendritic cells are much
lower.
1.2.5. Study approach
To eliminate a memory immune response due to previous influenza infections, I
examined cytokine production using naiVe equine (and human) peripheral blood
lymphocytes, and a human Jurkat T cell line. All influenza viruses tested were UV-
inactivated preventing viral replication. and therefore this model assays for the intrinsic
stimulation of the virus. Furthermore, to determine the importance of HA in cytokine
induction, viruses of the same HA but different NA subtype (H3N2 and H3N8) were
tested.
Briefly, naive human (and equine) peripheral blood lymphocytes, and a human
lurkat T cell line cells were pulsed with UV-inactivated influenza A viruses and an
influenza B virus. Following pulsing, stimulated lymphocytes were incubated for 3. 12
or 24 hrs prior to supernatant fluid collection and RNA extraction.
The amounts of RNA produced were assayed for using Reverse Transcriptase
(RT) and Polymerase Chain Reaction (PCR). This assay is semi-quantitative. The
amounts of cytokines released were determined using an Enzyme Linked Immunosorbent
Assay (ELISA). Cytokines assayed include IFN-y, lL-2, IL-4. IL-6. IL-IO and IL-12.
1.3. Future application/significance
The correlation between cytokine induction and severity of symptoms in influenza
infection could be used as a potential marker for the pathogenicity and virulence of new
influenza viruses. Additionally, an in vivo study of selected viruses regarding their
pathogenicity would enable development of an improved and longer lasting vaccine
strategy, for example, DNA vaccines [71, 92]. With education. and with massive
immunization campaign, a repeat of a pandemic like that occurred in 1918 will be
minimized if not prevented. Furthermore, this in vitro model could be used for
detennination of pathogenicity of other pathogens.
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CHAPTER II
LITERATURE REVIEW
2.1. Introduction
2.1.1. lnfluenw
Influenza, sometimes called Flu or Grippe, is an epidemic, acute, viral infection of
the upper respiratory tract [67]. Infection (in humans and other mammals) is initiated by
the inhalation of aerosolized droplets containing the virus. Initial infection is limited to
the epithelial lining of the respiratory tract. Onset of infection is sudden. and in the acute
phase fever ranging from 38 to 40°C is seen [11, 12]. These symptoms last from one to
five days. Other symptoms include chills, nausea, abdominal pain. diarrhea. a
generalized feeling of weakness, muscle pain, and soreness of the respiratory tract [12.
67]. Influenza virus infection can directly injure the nasal and tracheobronchial
epithelium, possibly as a result of virus-induced cellular apoptosis [12, 67]. The loss of
respiratory epithelial cells is a major reason for symptoms associated with influenza such
as cough, depressed trachobronchial clearance, and altered pulmonary function [12, 67].
2.i.2. influenza pandemics
Influenza A virus epidemics and pandemics have been recorded m European
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literature since the 17tD century. These records show large outbreaks in 1658, 1710.
1837, and 1889 [50]. In the twentieth century alone, three pandemics occurred in 1918,
1957, and 1968. The three different influenza virus subtypes responsible for th
twentieth century pandemics were HIN1, H2N2, and H3N2, respectively. Because of the
number of deaths, influenza virus can be considered one of the deadliest iruses of the
twentieth century.
The first pandemic of the twentieth century, the "Spanish Flu," occurred in 1918 and
caused, with conservative estimates, 20,000,000 deaths. It claimed the lives of as many
as one in 100 of the world's population at the time [79, 91]. The virus spread very
quickly through North America, Asia, and Europe. Even the Alaskan wilderness as well
as the remote islands of the Pacific did not escape [91]. The disease was named the
"Spanish flu" because it was first reported in a Spanish newspaper as a result of press
censorship in all the other countries mvolved in World War I. Approximately 28% of the
U.S. population was infected~ and the mortality rate averaged 2.5%, with a 70% mortality
rate seen in some isolated populations [91]. This was considerably higher than the
mortality rates from previous epidemics, which were usually around 0.1 % [91]. Besides
the high mortality rate, the "Spanish flu" differed from other epidemic as its primary
victims were young adults, a population thought usually to be unaffected by the disease.
The second pandemic, the "Asian Flu." occurred in 1957, and the third pandemic,
the "Hong Kong Flu," occurred in 1968. These two pandemics were not as deadly as the
pandemic of 1918. However, they caused much fear and suffering.
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2.1.2.1. Mortality and economical impact
Mortality due to influenza can be quite high. The 1'918 pandemic resulted in over
20,000,000 deaths. The 1957 pandemic caused an excess mortality of 70,000, while in
the 1968 pandemic the excess mortality was 30,000 [8, 24]. Deaths due to influenza are
not restricted to pandemics. An estimated 600,000 influenza-associated deaths ha e
occurred during epidemics between 1958 and 1990, with annual 20,000 influenza-
associated deaths in the United States alone between 1972 and 1991 [11, 14]. With the
recent finding that some avian influenza viruses can directly cross the species barrier -
from avian to mammal - and infect humans [47, 52, 68], makes the threat of the next
pandemic ever more frightening.
Despite all the advances ill medical technology and medical treatments
projections of fatalities if a pandemic similar in nature to the 1918 pandemic would have
occurred in 1998 are very high [SO]. The projections, shown in Table 2-1. suggest that
with shortened travel time, the virus could spread around the globe in just four days.
TABLE 2-1
PROJECTED FATALITIES FOR A 1918-LIKE INFLUENZA PANDEMIC IN
1998
Year
Population size
Principal type of transportation
Global spread of virus
Disease prevention
Disease treatment
Estimated deaths
Adapted from [50].
1918
1.8 billion
Ships, Trains
120 days
Gauze masks
Bed rest, aspirin
20 million
1998
5.9 billion
Airplanes
4 days
Vaccines
Antiviral drugs
60 million
In addition to the high mortality, the CDC has predicted a high economic impact,
including medical costs, for the United States if such pandemic occurs [58]. The cost.
forecasted to be around $ 70-166 billion, is summarized in Table 2-2. With the lack of a
lasting and effective vaccine for influenza (in addition to only a small percent of the
population being vaccinated) the economical impact is expected to be much higher [58].
Scientists at CDC argue that immunization of all "high-risk category' persons in the U.S.
will be more cost-effective [58]. However, what virus is going to cause a new pandemic
is unknown. Therefore, there is an urgent need to develop an in vitro model that allows
the identification of a potentially pandemic influenza virus. The use of this model may
minimize the medical and economical impact, ifnot prevent a new pandemic.
TABLE 2-2
AN ANNUAL ECONOMICAL IMPACT OF INFLUENZA VIRUS INFECTION
IN THE U.S.
Causes
Death
Hospitalizations
Outpatient visits
Additional illnesses
Economic impact
Modified from [58].
9
Cases
89,000 - 207.000
314,000 - 734,000
18,000,000 - 42,000,000
20.000.000 - 47.000.000
$ 71.3 -166.5 billion
2.2. Influenza virus
1.1.1. Classification
Influenza virus is a member of the Orthomyxoviridae [19]. The term "myxo
refers to viruses that interact with the mucus of the body. while the term ortho is used to
distinguish it from another group of negative-strand RNA viruses. the paramyxoviruses
[19]. Influenza viruses are divided into three types: A, B, and C. Type A is the most
pathogenic of the three, and is a principal etiological agent of influenza epidemics or
pandemics [88]. Type B influenza virus on the other hand, causes a mild disease.
However, it can cause localized winter outbreaks, mainly in children [88]. Type C
influenza virus is of questionable pathogenicity for humans [88]. therefore it is the least
studied ofall influenza viruses.
2.2.1.1. Virion and genome organization
The shape of virion of the influenza A virus is spherical to cylindrical, as shown
in Fig. 2-1. The virion has an envelope made up of a lipid bilayer. Each virion contains
eight linear negative-sense, single-stranded RNA molecules. The size ranges from 890-
2341 nucleotides (nt). The virus nucleocapsid has a helical symmetry and is
approximately 6-9 nm in diameter and 60 nm long. However, the virus itself has no
defined shape. possibly as a result of budding during its release from the host cell [19].
The viral envelope contains matrix protein (M2), and embedded onto the lipid surface are
the two surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA). The core
contains eight RNA segments in association with a ribonucleoprotein (NP). Three
different polymerases. PA, PBI, and PB2. are surrounded by matrix-! (Ml) protein
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which forms the capsid. Two nonstruetural proteins NS1 and NS2 are important for
proper virus replication. Each segment encodes a single polypeptide, however segments
two and three both produce two templates by differential splicing. Therefore. a total of
ten viral proteins are encoded in the eight-segment genome.
Fig. 2-1, Electron-micrograph of influenza A virus. Reproduced from [49].
2.2.1.1.1. Hemagglutinin (HA)
The hemagglutinin plays an essential role in viral entry for influenza viruses. It is
a trimeric, type I, membrane glycoprotein, with an N-tenninal ectodomain and a C-
proximal anchor. The hemagglutinin binds to the sialic acid at the cell surface, hence
mediates virus attachment to the cell receptor. Glycosylation of the HA is believed to
II
play an important role in viral pathogenicity [76]. HA glycosylation sites are detennined
by specific amino acid sequence.
The viral genome is replicated by an error-prone RNA polymerase. hence a high
frequency of mutations. These mutations affect the number of glycosylation sites. and
has been shown to affect the ability of the HA molecule to bind to cellular receptors or to
interact with antibodies. The virulence of the virus is therefore altered by an increase or
decrease in its binding capacity [76]. The infectivity of influenza viruses requires a
proteolytic cleavage ofthe hemagglutinin precursor protein, HAo. into the HAl and HA2.
HAl and HA2 are linked by disulfide-bonds [42, 44]. The availability of this HA
activating protease in various cell types is thought to be responsible for the localization of
viral infection particularly in the pulmonary epithelium [43]. A single arginine residue
(basic amino acid) present at the cleavage site is believed to be responsible for tissue
tropism. However, it has been shown that some influenza viruses do not share this
restriction. Mammalian and nonpathogenic avian influenza viruses have HAs that are
usually cleaved only by a few cell types [36, 82]. Hence. they can only cause local
infections [36, 82]. In contrast, highly pathogenic avian influenza viruses. such as H5
and H7, have HAs that can be cleaved by furin and other ubiquitous proteases present in
multiple cell types. thus permitting these viruses to cause systemic infections [59. 82].
These highly-cleavable HAs have multiple basic amino acid residues forming a
consensus sequence, Arg-X-Lys/Arg-Arg. However, the HA sequence of highly
pathogenic 1918 (HlNl) virus differs from highly pathogenic avian influenza viruses
[86]. Pathogenicity of 1918 (H 1N1) virus has been attributed to viral adaptation within
the human host, possibly several years before the 1918 pandemic [72].
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2.2.1.1.2. Neuraminidase (NA)
Neuraminidase contains an N-proximal anchor and a C-tenninal ectodomain. It
cleaves the a.-glycosidic linkage between sialic acid and an adjacent sugar residue.
therefore preventing virus self-aggregation and allowing the release of the virus from an
infected cell [27]. The sialic acid serves two functions: 1) it blocks viral assembly. and 2)
it becomes incorporated into the mature virus particle. Several studies focus on the
importance of NA in infection. For example, Goto ef 01. [27], proposed a possible
mechanism for cleavage of the pandemic 1918 (HINI) influenza virus involving NA.
They suggested that the NA binds and sequesters tissue plasminogen. leading to a higher
local concentration of this ubiquitous protease precursor [27]. This results in an
increased cleavage of HA, hence leading to higher pathogenicity [27]. The structural
basis for this unusual property appears to be by the presence of a lysine at the carboxyl-
terminal end, and the absence of an oligosacharide side chain at position 146 [27].
2.2.1.1.3. Matrix proteins (M I and M2)
Matrix-1 protein is the most abundant viral protein. It is located direct ly beneath
the lipid envelope. The function of M1 is to form the capsid for the assembly of progeny
VIruS. Matrix-2 protein is a product of an alternate spliced transcript of the RNA
segment. It is an integral membrane protein. and believed to function as an ion channel
for pH control. It is an essential factor for virus maturation and cell entry [39, 85].
2.2.1.1.4. Nucleoprotein (NP)
Nucleoprotein provides structural support to the RNA genome. It forms the
backbone of the helical complex associated with each of the eight RNA segments. and
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with three different virion polymerases.
2.2.1.1.5. Polymerases (PA, PBl, and P82)
Polymerases are responsible for carrying viral transcriptase activities. Polymerase
A (PA) is an acidic viral protein, and is believed to be responsible for virion RNA
synthesis. Polymerase B1 (PB 1) and polymerase 82 (PB2) are basic viral proteins. and
they are implicated to complement RNA synthesis.
2.2.1.1.6. Nonstructural proteins (NS 1 and NS2)
Non-structural protein-1 (NS 1) and Non-structural protein-2 (NS2) are found in
abundance in infected cells during virus replication. However, they are not incorporated
into progeny virions. Both of these proteins are translated from alternate spliced mRNA
transcripts.
2.2.1.2. Replication
Viral infection is initiated by the binding of the globular head ofHA region to cell
surface sialic acid residues. Following the binding, viruses are translocated into the cell
by endocytosis. During endocytosis, the low pH in endocytotic vesicle leads to a
conformational change in the HA molecule. This conformational change allows the
amino terminus of HA2 to insert into the vesicular membrane and results in fusion of the
viral envelope and the vesicle membrane. Release of virion content into cytoplasm soon
follows. The NP migrates to the nucleus, and NP associated polymerase starts
transcription of early viral proteins, NP and NS I. Since virion transcriptase complex is
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unable to self-initiate viral mRNA synthesis an RNA endonuclease cleaves the 50
tenninal fragments from capped and methylated mRNA (10-14 nt long) from the host
cell. Newly synthesized NP and NSI proteins migrate to the nucleuso and initiate
complementary RNA and negative viral RNA synthesis. RNA-dependent RNA
polymerase is involved in the synthesis of positive-sense strands from the negative-sense
template [19].
Newly synthesized viral RNA segments are encapsulated with NP, and used as
secondary templates for the transcription of Ml, HA, and NA proteins. Nucleocapsids
are enclosed by MI, followed by transportation to the cytoplasm for assembly.
Interaction between MI, HA, NA, and M2 appears to serve as the initiation signal for
virus budding. Enzymatic activity of neuraminidase results in the virion release from the
host cell, while extracellular cleavage of HA into HA1 and HA2 by host proteases is the
fmal step of viral maturation [19]. A summary of influenza virus replication is shown in
Fig. 2-2.
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Fig. 2-2. Replication of influenza virus. Seven steps involved in viru r plication are; I) ad 'Orption; )
penetration; 3) uncoating; 4) viral genome replication and transcription of viral gen ; 5) tran Ilation; 6)
a sembly; and 7) release.
2.2.1.3. Antigenic subtypes
Influenza viruses are divided into several subtypes. based on their antigenic
differences for the HA and NA [19]. Antigenic differences and eros. -reactivity are
detennined using post-infected ferret serum. So far, 15 different HA and 9 different NA
subtypes, have been identified. All of these subtypes have been isolated from avian
species, making avian species a natural host of influenza virus [3, 84]. Out of these
subtypes, only five are pathogenic for humans and three of them have caused pandemics
[3, 84].
16
The nomenclature for influenza virus is based on the virus type, the host species
(if human virus, no host designation is necessary) the geographic origin, isolate number,
and year of isolation. The antigenic classification is always stated in the parenthesi
following the standard nomenclature, e.g., A/Japan/305/57 (H2N2). A summary of
influenza virus isolates is shown in Table 2-3.
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-TABLE 2-3
ORIGIN OF SPECIES OF INFLUENZA A VIRUS SUBTYPES
Humans Swine Horses Birds
Hemagglutinin:
HI PR/8/34 SwflalI5/30 Dk!Alb/35/76
H2 Sing/1/57 Dk!GerI1215/73
H3 HK/l/68 Sw/Taiwan/70 EqlMiami/I/63 DkJUkr/l/63
H4 Dk!CzJ56
H5 HK/156197 Tem/S.A./61
H6 TylMass/3750/65
H7 Eq/Prague/ I/56 FPVlDutch/27
H8 Ty/Ont/6I18/68
H9 HK/1/99 Ty/Wisl1/66
HIO Ck!GerlN/49
HI I DklEng/56
H12 Dk!Alb/60/76
H13 Gull/MD/704/77
H14 Dk!Gurjev/263/82
HI5 Ok!Austral/34 1/83
Neuraminidase:
N1 PRJ8/34 Swflal15/30 Ck!Scot/59
HK/156/97 SwlTaiwan/70
N2 Sing/lI57 TyfMass/3750/65
HK/l/99
N3 Tem/S.A.l6l
N4 Ty/Ont/6II8/68
N5 Sh/AustraV1/72
N6 Dk!CzJ56
N7 Eq/Prague/1156 FPVIDutchl27
N8 EqlMiami/lI63 DkJUkrll 163
N9 Dk!Mern/546174
Primary isolated subtypes of influenza A virus. Of the equine influenza A viruses. equine-2 (H3N8) and
equine-I (H7N7), cause clinically more and less severe disease in horses respectively. For human
influenza A viruses. HINI, HlN2, and H3N2. have caused pandemics in 1918. 1957. and 1968
respectively. IsolatiOl1 of H5Nl and H9N2 avian influenza viruses in humans indicates a possible direct
species crossing between the two species. The H5Nl subtype appears to be highly pathogenic (33% case-
fatality-rate), on the contrary, H9N2 causes only a mild disease. No virus isolate is presented by the dashed
lines (-).
18
-2.2.1.4. Antigenic Shift and Drift
The two known features of influenza virus that account for its epidemiological
success are: 1) antigenic shift and 2) antigenic drift [19].
2.2.1.4.1. Antigenic shift
Antigenic shift occurs only in influenza A viruses. and is believed to be the
mechanism responsible for the past pandemics [19]. It is defined as the sudden and
drastic change in virus antigenicity, resulting in emergence of novel type A influenza
viruses [19]. In antigenic shift, segments of the RNA genome from two genetically
distinct strains of influenza virus that have infected the same cell become associated. The
mixed and reassorted RNA results in generation of reassortant viruses [94]. This
reassortment can occur in any species. However, swine seems to be involved because
they are susceptible to both avian and human viruses [19]. The reassorted viruses do not
have to emerge through the same lineage; therefore, several different viruses can reassort
and emerge at once [97]. The HA and NA molecules of the newly. reassorted viru may
differ;- at the amino acid level, anywhere from 20-50% from the previously circulating
strains [11]. Hence, the change in the surface antigens of the virus makes it
unrecognizable to the antibody elicited by a previous infection or immunization process
[3. 25]. This can lead to a higher attack rates for the new virus. and hence establish itself
in humans.
2.2.1.4.2. Antigenic drift
Antigenic drift is limited to type A and type B influenza viruses [19]. It is defined
19
as a rapid and unpredictable antigenic change, a result of point mutations in viral surface
proteins, mainly HA [19]. Antigenic drift is likely to occur as a result of the selection
pressure exerted on the virus by host immunity. Viruses that evade host immunity b.
changing the amino acid composition at their epitope remain infectious, while unchanged
viruses are neutralized by the host immunity. Antigenic drift variants are known to be
responsible for annual epidemics that occur between pandemics [II, 90]. Influenza
viruses isolated from aquatic birds show no evidence of net evolution over the past 60
years [17, 26]. However, their nucleotide changes (in their HA and NA) appear to occur
at rates similar to human influenza viruses [17, 26]. suggesting that immune selection is
partially responsible for antigenic drift.
2.2.1.5. Geographic Determination and Reassortment Spec{ficity
Since most of the pandemics start in Asia, it has been speculated that the next flu
pandemic may also come from that region [25, 32]. One reason is that the lifestyle
considered to be ideal for viral gene mixing (reassortment) is found in Asia. more
specifically, in China [90]. Live bird markets, housing a variety of avian species and pigs
in close proximity, are considered to be ideal place for such an interaction [90]. Swine
species are considered "mixing vessels" for influenza viruses. Swine species exhibit a
low species barrier to both avian and human influenza A viruses [3, 25, 53]. Pigs have
both, NeuAc-2,3Gal (human) and NeuAc-2.6Gal (avian) receptors required for the
attachment of influenza virus to epithelial cells. On the contrary, the avian influenza
viruses are not readily introduced into humans, possibly because humans do not possess
the' a-2.3-sialyllactose (NeuAc-2,3Gal) receptors [5]. Continued replication of avian
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-influenza viruses in swine allows the avian viruses to mutate and to recognize human cell
surface receptors [38], therefore increasing the chance of transmission to human species
[37]. Following the infection of a new avian or mammalian hosts. influenza viruses
evolve rapidly, usually causing a mild respiratory infection [53].
2.2.1.5.1. Direct crossing of the species barrier
Until 1997, it was believed that pigs were required as the "mixing vessels" for
human infection. However, the recent introduction ofavian influenza to humans in Hong
Kong [47, 68, 84], suggest that this hypothesis has to be reconsidered. A new theory
suggesting the possibility of direct barrier crossing between avian and human species
may be happening more than previously thought.
During the 1997 "Chicken Flu" outbreak in Hong Kong, a previously unknown
influenza virus, of subtype H5N 1, was iso tated from a three-year-old boy hospitalized
due to influenza related symptoms. This novel human H5NI influenza virus was shown
to be identical to the avian H5Nl influenza virus [47, 80] causing high mortality in
chickens at that time. This H5Nl virus is capable of causing systemic infection m
chickens by replicating in neurons and vascular tissues [45]. Preventive measures were
taken to reduce further spread of this higWy pathogenic influenza virus. Since the initial
outbreak of H5N 1 in May 1997, Hong Kong, eighteen confirmed cases of human
infection have been reported, of which six were fatal (case-fatality-rate of 33%) [80].
The high pathogenicity ofH5Nl in humans and chickens, is probably attributed to a large
proportion of amino acid substitutions in all gene products except in the hemagglutinin
and neuraminidase genes [83].
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A second introduction of avian influenza to humans occurred in April 1999. Hong
Kong, when two girls were hospitalized with flu like symptoms [68). The patients, a one-
year-old-girl and a four-year-old girl, were admitted to the hospital with fever. malaise.
anorexia, sore throat, headache, abdominal pain, vomiting, and inflamed oropharynx.
Both patients recovered within three days and were discharged. A new strain of
influenza virus (H9N2) was isolated, and identified to the previously-isolated avian virus
[68]. The difference in clinical symptoms and mortality caused by H5Nl or H9N2
suggests a difference in their pathogenicity. Despite the lower pathogenicity of the H9N2
virus, a significant threat exists because H9N2 influenza A virus is now widespread in
poultry in Asia. Avian H9N2 influenza virus has been shown to be a donor of the
internal genes ofH5Nl subtype [31] [52).
The last two episodes of H5Nl and H9N2 outbreaks indicate the capability of any
avian influenza virus to infect humans. The high pathogenicity ofH5Nl virus is a major
concern., however the reasons for its low transmission are unclear. It is fortunate that
H5Nl can rarely be transmitted from human to human, thereby preventing its spread.
Influenza pandemic occurs every 20-30 years. However. the ability of avian
viruses to directly cross the species barrier, and the observable difference in viral
pathogenicity, suggest that the next pandemic could occur at any time with devastating
consequences [14). The need for an in vj{ro model that can identify the potential
pathogenicity of avian influenza viruses would be of great significance. Such a model
will assist us to predict and prevent any future outbreaks, epidemics, or pandemics.
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2.3. Immune response
2.3.1. Introduction
Infection by influenza elicits a cascade of immune responses, leading to a
mucosal inflammation with the influx of plymorphonuclear cells lymphocytes. and
macrophages into the respiratory mucosa [67]. While this response leads to the
resolution of the infection and protection against re-infection, it also contributes to the
development of local systemic symptoms. The factors responsible for this are not
completely understood [67]. A simple explanation implies that the respiratory symptoms
of influenza result from direct cytopathic effects of the virus, and that the systemic
symptoms are caused by production ofcytokines [33].
During an infection., the innate, as well as both arms of adaptive immunity are
activated. Innate immune responses are initiated early and do not depend on
immunologic memory [73]. They are mediated by interferon type I and II cytokines [73],.
The adaptive immune responses, on the other hand involve both, cell-mediated and
humoral immune responses [66]. Adaptive immune responses require antigen
recognition, processing. and presentation, and cellular activation and differentiation.
Adaptive immune responses, therefore playa role later in infection than the innate
responses.
1.3.2. The innate immune response
Little is known about the initial stages of the immune response in influel17A virus
infection prior to emergence of specific antiviral effector mechanisms. During the initial
phase of infection, influenza virus interacts with the cells on the luminal side of the
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airways to induce the release of immunoactive mediators. The chemokine attract
infiltrating cells to the site of infection and process antiviral activities. This is an early
defense against viral infection. Induction of pulmonary inflammation appears to be
particularly important for antigen translocation to the lymphatic tissue from the lungs.
This also leads to the recruitment, immigration. and activation of virus specific
lymphocytes.
Innate immunity ill influenza virus infection relies on macrophage responses.
Macrophages-mediate lysis of infected cells and act as antigen presenting cells (APes)
[54], along with dendritic cells [96). IFN-a., IFN-P, and IFN-y release activates natural
killer cells (NK) and prevents viral spreading by lysis of virus-infected cells. In addition.
production of pro-inflammatory cytokines such as IL-!, IL-6, and TNF-a. suppresses viral
replication [6, 66, 70].
Another branch of the innate immune response is the complement system. It is
activated by either the alternate pathway (in the absence of the antibody), or by the
classical pathway (in the presence of antibody) and can lead to lysis of infected cells [73).
2.3.3. The adaptive immune response
There are two branches of the adaptive immune responses. They are cell-
mediated immune response and the humoral immune response.
1.3.3.1. The cell-mediated immune response (eM!)
The cell-mediated immunity involves CD8+ lymphocytes. NK cells, ADCC. etc..
antigen recognition, cytotoxic mediation such as TNF, and cytokine production by
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activated cytotoxic T-cells [73]. This response system depends on antigen recognition
and cytokine production by macrophages and T cells. CD8+ T-cell initiation of cell lysis
requires the association of antigen with MHC [73]. This association leads to
simultaneous stimulation of macrophages to produce IL-l and activation of T-cells to
produce IL-2. Interleukin-2 release leads to activation and proliferation of other I-cells
resulting in additional cytokine release [21], [87J and eventually to destruction of an
infected cell.
The humoral immune response is important for protection against cell-free virus.
and prevention of re-infection by a homologous or antigenically-similar virus. The
factors in the development of the humoral immune response are different from the cell-
mediated immune response. The development of humoral immune responses is usually
preceded by the cell-mediated responses [73J. However, antibody production provides a
lasting and persistent protection [73J. Development of memory cells is essential in the
activation of an immune response towards future infections. Th2 type cytokines promote
proliferation and transformation of B-Iymphocytes into antibody-secreting plasma cells.
It has been shown that B-cell deficient mice have increased susceptibility to lethal
infection by influenza viruses. [29J
Early in the humoral response, IgM antibody is produced [73], which is followed
by the IgG synthesis and development of a mature immune response (secondary
response). A summary of the cell-mediated and the humoral immune responses is shown
in Fig. 2-3.
The humoral immune response2.3.3.2.
-
25
po
Fig. ~3. Development and activation of the cell-mediated immune response and the humoral
immune response. The upper right half hows development of CMl. The lower left half how
development of humoral immune response. Both Th I and Th2 cells receive their fir 1 activation ignal
from an interaction with an APC. The second activating signal for Th I cells i the relea cd IL-12, while
Th2 cells are further activated by IL-I. Activation of helper T cells leads to development of either cell-
mediated or hwnoral immune responses.
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2.3.3.3. Thl and Th2 dichotomy
The two types of adaptive immune response, the cell-mediated and humoral,
complement each other in virus elimination, killing of virus-infected cells, and in
recovery [73]. T-Iymphocytes playa primary role in recovery from viral infections.
Recently, T-helper cells have been classified into Th I and Th2, based on the type of
cytokines they secrete [65]. The functions of Thl and Th2 cells are very different.
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Although both Thl and Th2 cells provide help for B-cell activation, Th2 cells playa
more active role. On the other hand, the Thl cells preferentially induce delayed-type
hypersensitivity and are important for macrophage activation [29].
Recovery from viral infections is predominantly regulated by the cellular immune
response, or more specifically, by CD8+ T cells. Cytotoxic T cells (CD8+) induce lysis
of infected cells, hence preventing the production of progeny virus. CD4+ T cells
respond to viral peptides presented on MHC II molecules by the release of cytokines.
The cytokines have different functions; serving as growth factors for CD4+ and CD8+ T
cells, maturation and differentiation of B-cells, and for inflammation initiation. CD4+ T-
cells, after stimulation are differentiated into either Thl or Th2. Thl type produces large
amounts ofIFN-y, which leads to the generation of cytotoxic T-cells (CTL). while Th2
cells produce other cytokines and control activation and suppression of CTL. B-cells. on
the other hand, are activated by Th2 cytokines. However, in the presence of Thl
cytokines, B-cells are induced to produce complement activating isotypes (murine
IgG2a). In contrast, non-complement activating mouse IgG 1 is the predominant isotype
in Th2 response. [61]
2.4. Cytokines
2.4.1. Roles in infection
Cytokines are small proteins secreted from a variety of cells in response to an
infection or tissue damage [73]. Cytokines are mediators of a network of intercellular
communication for immune cells. They are produced during the innate and the adaptive
imrriune responses [73]. Cytokines induce localized effects. however excess production
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results in systemic effects. Cytokines bind to specific receptor found on the surface of an
effector cell. This binding leads to activation, proliferation, and cytokine release in the
effector cell [16, 40, 66]. Cytokines have been shown to play an important role m
defense against influenza virus infection and other pulmonary viruses [66. 69].
Influenza virus infects and replicates in macrophages, resulting in induction of
cytokine. Cytokines may also contribute to the pathogenesis of the infection. by an
increased production of inflammatory cytokines. In response to influenza virus infection.
levels of IL-6, TNF-a, IFN-y, IL-IO, monocyte chemotactic protein-l (MCP-I).
macrophage inflammatory protein-l a CMIP-1 a.) and 1~ (MIP-1 ~) are elevated in the
nasal lavage fluid ofhuman volunteers [20]. This elevation correlates with the magnitude
and the duration of symptoms [20]. As shown by Hayden el al. [33], patients challenged
with influenza virus have a peak level ofIL-6 and IFN-a in nasal lavage fluid around day
two. This correlates to maximum virus titers, elevated body temperature, increased
mucus production... and higher symptom scores [20]. Skoner el al. [81], also report a
correlation between the days of viral shedding and levels of IL-6 and other measure of
symptoms. A summary of both Th1 and Th2 cytokines involved in pulmonary infections
and of particular importance to our study is presented in Table 2-4.
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TABLE 2-4
CYTOKINES ASSOCIATED WITH PULMONARY INFECTIONS
CytoldDr5 ProdUttiOD sourt~
IFN-y Macrophages and yo T cells~
NK cells and T lymphocytes
MttbllDums or DttiOD
Anti\'iral activity through stimulation
of MHC class I expression and
immune cytotoxici~
IL-IO
d by A('m-Dted by
T F.IL-~
IL-6
IL-12 Macrophages and B lymphocytes
IL-2
Th2 tree:
IL-4
T lymphocytes
Macrophages. mast cells, T and
B lymphocy1es. and basophils
Stimulation and differentiation ofT
and B lymphocytes. and aClivation
ofNKcells
Increase in activity ofNK cells. CTL.
and macrophages
Differentiation of B cells. B cells
isotype switching to IgE and IgG4
IL-IO
IFN-y
IL-I
IFN·y
Thl~1okines
Th2 ~·tokines
IL-5 T lymphocytes. eosinophils, and Stimulation and differentia! ion ofB Th2 cylokines
mast cells lymphocytes and eosinophils
lL-6 Epithelial cells. endothelial cells T cell activation and proliferation. CTL IL-4 IL-I
mast cells, monocytes, macropltages, differentiation., B cell differentiation IL-IO (L-2
hepalocytes, fibroblast. and leading to mucoSllllgA production.. and TNF·a
T lymphocytes pyrogenic effects
IL-IO Macrophages, monocytes. T and B Stimulation ofB lymphocytes. inhibition IFN-y Th2 cytok ines
lymphocytes of macrophage activity leading 10 Th I cytokines
suppression oflFN.y
Cytokines involved in pulmonary infections, assayed for in our study.
2.4.2. Th 1 vs. Th2 summary
Thl and Th2 cells indirectly regulate each other by cytokine production following
the interaction with an APe [65]. Th2 cells inhibit the function of macrophages, which
are the main source ofTh! response development [65]. On the contrary. Thl cells inhibit
the proliferation and function of B-cells necessary for the development of Th2 responses
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[65]. As a result of such cross-regulatory phenomenon cytokine mediat d inunune
responses, can only be changed during the response development and not aft r tb
conversion has taken place [I 10,28,51 63,65]. A summary of the cytokin interaction
cross-regulation, and function is shown in Fig. 2-4.
Fig. 2-4. Role of cytokioes. The characteristics of each Th 1 or Th2 cytokines is ba ed n the typ of the
immune response they elicit. 101 type cytokines (blue box), produced by 10 I lymphocytes elicit ceJl-
mediated immune responses. Th2 type cytokines (red box), produced by Th2 lymphocytes elicit humoral
immune responses. Cytokines (yellow boxes) suppres production of the other type.
2.5. Concluding rema rks
]n this study, I attempt to establish an in vitro model for cytokine induction by
influenza virus, using RT-PCR and ELISA. It is followed by determining if there is a
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-correlation to pathogenicity. Furthermore, I attempt to correlate this induction with viru
pathogenicity. Production and secretion of cytokines during an immune response has
been associated with influenza symptoms development [22, 33, 81]. Cytokines such as
IL-l p and IL-6 are associated with chills and fever development [22], while IFN-y is
associated with weakness, muscle pain, and upset stomach. Although. cytokines such as
IL-2. IL-4, IL-5, IL-lO, and IL-12 are not directly implicated in the development of
symptoms, they regulate the production of IL-l p, IL-6, and IFN-y. Furthennore. b~
using a pane] of influenza viruses with different degree of pathogenicity. this model
provides a system to test if the level of cytokine induction is correlated to in \'ivo
pathogenicity.
31
CHAPTER III
MATERIALS AND METHODS
3.1. Materials
3.1.1. Medium
3.1.1.1. RPM!:
RPMI 1640 (GibcoBRL, Grand Island. NY) was used for cell washing during
lymphocyte purification. To the RPML 15 ~g L-glutamine (Cellgro. VA) in 1 ml of
medium and 1% NaHC03 (Cellgro) were added. Antibiotics such as gentamycin
(GibcoBRL), amphotericin, penicillin, and streptomycin (Cellgro) were added to a final
concentration of 10 ~g/ml, 0.5 ~g/ml, 5 fl.glrnl. and 10 /lg/ml ofmedium respectively.
:-
..
,
..
..
I
.:
..
3.1.1.2. Optimum RPM/:
Optimum RPMI medium was used for cell adaptation. It contained the following:
-
RPMI 1640, L-glutamine, 1% NaHC03, gentamycin, amphotericin. penicillin.
streptomycin, and 10% w/v FBS (Fisher, Pittsburgh, PA), in a final concentration of 15
~g/rnl, 10 /lg/mt 0.5 ~g/ml, 5 ~g/ml, and 10 /lg/ml of medium respectively.
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-3.1.1.3. Optimum Opti-MEM I:
Opti-MEM I media (GibcoBRL, Grand Island, NY), with L-glutamine, 1%
NaHC03, gentamycin, amphotericin, penicillin, and streptomycin. in the fmal
concentrations of 15 J.1g1ml, 10 J.1g1ml, 0.5 J.1g/ml, 5 J.1g1mL and 10 J.1g1mJ of medium
respectively.
Both optimum RPM! and optimum Opti-MEM were used for cell adaptation and
culturing at 37°C and 5.0% CO2 for 3, 12, and 24 hours.
3.1.2. Polymerase chain reaction (peR)
3.1.2.1. Oligonucleotide primers for cytokine detection:
The cytokine oligonucleotide primers listed in Table 3-1 were used for amplification of
cytokine cDNA using PCR .
TABLE 3-1
UNIVERSAL CYTOKINE OLIGONUCLEOTIDE PRIMERS
)
,
..
..
..CYTOKINE FORWARD REVERSE FRAGMENT 01
IL-2 GCACCTACTTCAAGCTCTAC GATGCTTTGACAAAAGGTAATC 382 bp
IL-4 TATTAATGGGTCTCACCTACCA TTGGCTTCATTCACAGAACAG 411 bp
IL-6 CTATGAACTCCCTCTCCACAA TGCCCAGTGGACAGGrrTCl' 711 bp
IL-IO TACTTGGGTTGCCAAGCCTT TTCACAGAGAAGCTCAGTAAAT 495 bp
IL-12 AGATGCTGGCCAGTACACCT TGATGATGTCCCTGATGAAGA 475 bp
IFN-y ArnTGAAGAATTGGAAAGAGG AAATTCAAATATTGCAGGCAGG 367 hp
G3PDH CCTTCATTGACCTCAACTACAT CCAAAGTTGTCATGGATGACC 256 hp
• Universal cytokine oligonucleotides are obtained from domestic mammal consensus sequences according
to Rottman 1. B. el at. [74].
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-TABLE 3-2
3.1.3. En1J7me linked immunosorbent assay (ELISA)
PRIMARY AND SECONDARY ANTIBODIES FOR CYTOKINE ASSAY
Cytokine antibodies:
The antibodies for cytokine assay used in this study are listed in Table 3-2.
3.1.3.1.
Type Cytokine Produced in Company
Primary ,
..
IL-2 Goat R&D ..
1L-4 Goat Sigma
IL-6 Goat R&D
IL-IO Rat PharMingen ),
IFN-y Rabbit Chemicon
..
..
Secondary
1L-2 Rabbit anti-Goat IgG Chemicon
lL-4 Rabbit anti-Goat IgG Chemicon
1L-6 Rabbit anti-Goat IgG Chemicon
1L-10 Goat anti-Rat IgG Sigma
IFN-y Goat anti-Rabbit IgG Chemicon
Standard
IL-2 Recombinant human R&D
IL-4 Recombinant human Sigma
lL-6 Recombinant human R&D
lL-10 Recombinant human R&D
IFN-y Recombinant human Sigma
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3.1.4. Cell types
3.1.4.1.
3.1.4.1.1.
Peripheral blood lymphocytes
Adult human peripheral blood lymphocytes
BLood was obtained from adult volunteers at the Student Health Center.
Oklahoma State University, Stillwater, OK. Ten to fifty milliliters of blood was drav.,n
(by the registered nursing staff) from the median cubital vein, followed by transfer into
10 rnl "green top" test tubes containing sodium heparin anticoagulant (Becton Dickinson.
Oxnard, CA).
3.1.4.1.2. Human umbilical cord blood lymphocytes
~
..
..
..
Human umbilical cord blood was obtained from the Maternity Ward at Stillwater
Medical Center (SMC). Umbilical cord blood was collected by gravity, from discarded
umbilical cords post-partum. Twenty to thirty milliliters of cord blood was collected into
a 50 rnl centrifuge tube containing 5 rnl total volume of sodium citrate anticoagulant (32
mg/ml sodium citrate and 4.2 mg/ml of citric acid).
(A copy of OSU-IRB approval and a consent form can be found in the appendix
section. Name, race. age, or sex of any party involved remains unknown).
..
..
•
:
..
3.1.4.1.3. Equine peripheral blood lymphocytes
Fifty to one-hundred milliliters of blood was obtained from non-vaccinated one to
two year-old horses housed at Equine Research Park, Oklahoma State University.
Stillwater, OK. The blood was drawn from the jugular vein then collected into lO ml
"green top" test tubes. The horses were purchased as foals. They have not been
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-vaccinated for influenza., or have any history of exposure to equine influenza virus. To
exclude previous exposure to equine influenza virus an III test was performed on
collected serum.
3.1.4.2. Chicken red blood cells
Chicken blood was obtained from the chicken facility at the Department of
Poultry, College of Agriculture, Oklahoma State University, Stillwater. OK. The blood
was drav.n from the subclavian vein with a "butterfly needle" connected to a 5-ml
syringe. Collected blood was transferred into a 5 rnl "green top" test tube. To prepare a
2.5% chicken-red-blood-cell suspension, the erythrocytes were washed and diluted with
PBS to 2.5 %. This chicken-red-blood-cell suspension is used for hemagglutination and
hemagglutination inhibition tests. ).
..
..
3.1.4.3. Jurica! T cell line
The Jurkat cell line, a pseudoploid human T cell leukemia cell line (ATTC catalog
number TIB-152), was kindly provided by Dr. Mats, College of Agriculture. Department
of Biochemistry and Molecular Biology, Oklahoma State University. Stillwater. OK.
Cells were maintained in optimum RPMI at 37°C and 0.50% CO2 in a water-jacketed
incubator (Revco, Ultima). For virus infection. cells were synchronized at the log phase
by passage 24 hours prior to infection.
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3.1.5. Influenza viruses
Influenza viruses of different types, subtypes and strains used in this study for
infecting lymphocytic cells are listed in Table 3-3.
TABLE 3-3
INFLUENZA VIRUSES USED IN THIS STUDY
Type Subtype Host Virus strains Genbank accession no.
Influenza A
HINl humans AlPuerto Rico/8/34/ VOI088
HINl humans A/New Jersey/1ll76 KOO992
H2N2 humans AlJaparv'305/57 L20407
H3N2 humans AIAichi/2/68 J02090
H3N2 humans AlPanama/99* ND
H3N8 equme AlEq/Miamill/63 M24719
H3N8 equme AlEq/Saskatoorv'l/90 AFl97243
H3N8 equme AlEq/Kentucky/l/97 AF197249
H3N8 equme NEq/Kentucky/1/98 AF197241
H7N7 equine AlEq/Prague/56 X62552
Influenza B
humans B/Lee/40 KOO423
* A gift from Dr. Nancy Cox. CDC, Atlanta, GA. ND = not determineo.
3.2. Methods
3.2.1. Lymphocyte purification
The protocol for lymphocyte purification adapted with modifications from Grimm
el.al. [30], and Mawle el.a!. r561. Briefly, purification of lymphocytes from sialic acid
containing erythrocytes was critical. Attachment of virus to the sialic acid on
erythrocytes would interfere with the stimulation of lymphocytes. resulting In
misrepresentation m quantity and type of cytokines induced following infection.
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Lymphocytes were purified using Lymphoprep solution (NycoMed, Oslo, orway).
Thirty milliliters of Iymphoprep medium were placed into a 50 ml tube, 15 ml of a blood
sample was gently layered on the top of lymphoprep solution. Tubes were centrifuged at
500x g for 60 min. Using sterile pipettes, the lymphocyte-containing middle-white layer
was collected and transferred to a new 50 ml centrifuge tube. Lymphocytes were washed
twice with RPMI medium, gently shaken and centrifuged at 400x g for 10 min.
Supernatant fluid was discarded, and the lymphocyte pellet was washed twice with ]5 ml
of RP:MJ medium and cultured in optimum RP:MJ medium at 37°C and 5.0% CO2 for
cell synchronization.
3.2.2. Cell culture
3.2.2.1. Synchronization oflymphocytes
Lymphocytes, obtained from fresh blood, or from cell culture, were sub-cultured
for 24 hrs in optimum RPMI. Supernatant fluid containing FBS could potentially be
cross-reactive to cytokines, therefore it was removed by centrifugation at 400x g for 10
min, followed by an addition of RPM! medium.
3.2.2.2. Culturing oflymphocytes
Lymphocytes were resuspended m 1.0 ml of optimum Opti-MEM I medium,
counted, and adjusted as necessary to a fmal concentration of 2.5x 106 cells/mt.
Lymphocytes were pulsed with influenza viruses for 4 hrs, followed by 3, 12, or 24 hrs
incubation at 37°C and 5.0% CO2 in 1.0 ml fresh. virus-free optimum Opti-MEM I
medium. Following this incubation. cells were centrifuged for 5 min at 400x g, and
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supernatant fluids were collected for quantification of cytokine production by ELISA.
Cellular RNA was extracted, using a total RNA extraction method, and subjected to a
semi-quantitative analysis by RT-PCR.
3.2.2.3. Cell count
The cell count protocol was adapted with modifications from George et.al., [23].
Briefly, 20 III of purified lymphocytes was mixed with 20 III of Trypan Blue (Cellgro.
VA) and incubated for 5 min at room temperature. Following the incubation. 10 III of the
cell-dye mixture was loaded onto a hemacytometer slide (Hausser Scientific. Horsham,
PA) and observed at 400X under a compound light microscope (Fisher Scientific.
Pittsburgh, PA). Cell number was determined and cell concentration was calculated.
3.2.3. Influenza viruses
3.2.3.1. Propagation ofinfluenza viruses
The protocol for virus cultivation was adapted with modifications from Hierholzer
et.a!., [34]. Briefly, influenza viruses were cultivated in the allantoic cavity of 9 to 11
day-old embryonated chicken eggs for 72 hrs at 37°C. Following the incubation.
allantoic fluid was harvested. and centrifuged at 400x g for 10 min to clarifY the
supernatant fluid. The clarified supernatant fluid was assayed by a hemagglutination test
for virus concentration. Following the hemagglutination test. the allantoic fluid was
diluted in PBS to ]:] HA unitlml before being UV-inactivated.
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3.2.3.2. Hemagglutination test
Hemagglutination assay, protocol was adapted and modified from that described
by Hierholzer et. a/. , [34]. It was performed using 96-well microtiter Falcon plate
(Becton Dickinson, Oxnard, CA). Fifty microliters of allantoic fluid were serially diluted
with PBS, and 50 j..l.l of 2.5% chicken erythrocytes were added to each well. The plate
was incubated at room temperature for 30 min. Virus titer was determined by the
presence of hemagglutination at the lowest dilution.
3.2.3.3. Hemagglutination inhibition
The hemagglutination inhibition test was performed according to the protocol
from Chernesky [9], also using Falcon 96-well microtiter plates. Twenty-five microliters
of equine antiserum was serially diluted with 25 J.!l of PBS. Following the dilution and
30 min room-temperature incubation, 50 J.!l of 2.5% chicken erythrocytes were added to
each well. Thirty minutes after addition of erythrocytes, the titer was determined by the
absence of hemagglutination inhibition at the lowest dilution.
3.2.3.-1 Ultra-violet (UTI) inactivation
One milliliter of purified aUantoic fluid containing 1: I HA unit/ml of influenza
virus was aliquoted into a 35mm petri dish. The petri dish was placed on ice (with air-lid
open), 15 cm from a 10 W ultra-violet (254 run) light source, and irradiated for 10 min.
Following the UV-inactivation, the HA titer was re-assayed.
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3.2.3.5. Pulsing ofcells with influenza viruses
Lymphocytes at a concentration 2.5xl06 cells/ml were pulsed for 4 hrs with either
I or 10 units oflN-inactivated influenza viruses. Following a 4 hrs incubation. the cells
were centrifuged at 400x g for 5 min, and the virus-containing supernatant fluids were
removed. Cells were resuspended in fresh, virus-free, optimum Opti-:MEM I medium
and incubated at 37°C and 5.0% CO2 for 3, 12, or 24 hrs.
3.2.3.6.
3.2.3.6.1.
Controls
Negative control
Allantoic fluid obtained from virus-free 9 to II day-old embryonated chicken
eggs incubated at 37°C for 72 hrs was used as a negative control in human umbilical
cord blood and Jurkat T cell line experiments. Tissue culture grade PBS (Boehringer
Mannheim, Indianapolis, IN) was used as a negative control in human peripheral blood
and equine peripheral blood experiments.
3.2.3.6.2. Positive control
Pokeweed and Concavalin A (ConA) mitogens (GibcoBRL, Grand Island, NY)
were used as a positive control in umbilical cord blood and Jurkat T cell experiments at a
final concentration of 50 Ilg/ml and 500 Ilg/ml. Lymphocytes were pulsed with equal
amount (50 Ill) of each mitogen, negative control, and viruses.
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3.2.4. Assays
3.2.4.1. Total RNA extraction
The protocol was adapted with modifications from De Kossodo [15]. Briefly, to a
1.5 ml eppendorf tubes containing 2.5x106 cells/ml, 100 III of 10% SDS, 15 III of 1
mg/ml ProteinaseK (GibcoBRL) and 0.5 Jll of RNasin (GibcoBRL) were added. The
tubes were gently vortexed, and incubated at room temperature for 15 min. Following
the incubation, 10 III of 3M NaOAc (pH 5.2), 500 III of TRIZOL reagent (GibcoBRL,
Grand Island, NY) and 100 III of chlorophorm-isoamylalcohol mixture (24: 1) were
added. The tubes were vortexed and incubated on ice for 15 min.. followed by
centrifugation at 12000x g for 15 min. The upper aqueous layer was transferred to a new
tube and mixed with 2X volume of 100% Isopropanol (Sigma S1. Louis, MO). To
precipitate the RNA, tubes were stored at 4 °C for 15 min and centrifuged at 12000x g fo r
15 min. RNA peUets were washed with equal volume of 75% EtOH and centrifuged at
8000x g for 10 min. Following the centrifugation, supernatant fluids were removed. and
the RNA pellets were air-dried. RNA pellets were resuspended in 50 JlI sterile ddH20
treated with of 0.2 units RNasin.
3.2.4.2. Genomic DNA removal
Six microliters of total RNA, 1.0 ).ll of lOX DNase I Reaction Buffer. I FAI of I
U/).ll DNase I (GibcoBRL), and 2.5 III of 0.2 units RNasin treated sterile ddH20 were
mixed and incubated for 15 min at room temperature. One microliter of 25mM EDTA
pH 8.0 (GibcoBRL) was added to the mixture followed by 10 min incubation at 65°C.
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3.2.4.3. Reverse Transcription (RT)
Reverse transcription and peR were performed according to the procedure
described by Lai et.al., [48). Briefly, 10 ~l of DNase-treated RNA 1.0 ~l of2 mM Oligo
(dT) primers, 8.0 III of 0.2 units RNasin treated sterile ddH20 were added and incubated
at 70°C for 10 min. Following incubation, samples were placed on ice for 3 min. Four
microliters of 5X RT Buffer (GibcoBRL), 2.0 III of O. M DDT (GibcoBRL) and 4.0 III
of 2 mM dNTP were added and mixtures were incubated at 42°C for 2 min. After
incubation, 1.0 III of200 units/JlI M-MLV Reverse Transcriptase (GibcoBRL) was added
and the mixtures were incubated for 50 min at 42.0 °C, followed by incubation at 70.0 °C
for 15 min. This eDNA was diluted in 80 III of sterile ddH20 treated with 0.2 units
RNasin, and subjected to PCR.
3.2.4.4. Polymerase Chain Reaction (peR)
The standard PCR conditions were: 1.5 mM MgCb, 50 mM KCI. 10 mM Tris-
HCl (pH 8.3), 0.2 mM dNTP, and 2.5 U Taq DNA polymerase. 5.0 III eDNA, 1.0 III of
0.5 pM cytokine specific torward oligonucleotide, 1.0 III of 0.5 pM cytokine specific
reverse oligonucleotide, 1.0 III BSA, and 17 JlI of water in 25 III reaction mixture. The
samples were exposed to 35 cycles, denatured at 94.0 °C for] min. and 95.0 °C for 45
sec. annealed at 55.0 °C for 45 sec, extended at 72.0 °C for 1 min. and 72.0 °C for] 0 min
in a thermocycler (Perkin-Elmer. GeneAmp peR System 2400).
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3.2.4.5. Agarose gel electrophoresis
Five microliters from RT-PCR sample tubes were mixed with 5 ~I of tracking dye
(0.25% (w/v) bromphenol blue, 0.25% (w/v) xylene cyano~ 20% glyceroL 0.1 M EDTA.
pH 8.0) and loaded onto an 1.5% agarose gel. Five microliters of standard markers (l Kb
and 100 bp) were also mixed with the tracking dye and loaded onto gels. Electrophoresis
was run on 100 V for approximately 35 min using 1.5% agarose gels and TBE buffer (89
mM boric acid, 89 mM Tris, and 2 mM EDTA. pH 8.0). Following electrophoresis. the
agarose gels were stained in Ethidium Bromide (1.0 ~g/ml) for 15 min. An Alpha Imager
2000 (Alpha Innotech Corporation) was used to photograph and document the agarose
gel.
3.2.4.6. Enzyme-linked immunosorbent assay (ELISA)
ELISA was perfonned, by a modified protocol obtained from Meager [57]. Using
a Microtiter 96-well Nunc-Immuno plates with MaxiSorp surface (Nunc Brand Products.
Denmark), 15 ~l of supernatant fluids were serially diluted with 135 ~I of 50 mM
NaHC03 (pH 9.6), and incubated overnight at room temperature. Each sample was
assayed in triplicates.
Twenty-four hours after incubation, microtiter plates were washed with PBS (pH
7.4), and blocked with 2% BSA (Fisher Scientific. Pittsburgh. PA) in PBS and incubated
for 1 hr at room temperature. Following incubation, plates were washed with PBS. 100
~I of 1:2000 dilution of the appropriate cytokine primary antibody (R&D Systems.
Mineapolis, MN; Sigma, St. Louis, MO; PharMingen. San Diego, CA; and Chemicon.
Tamecula. CA). in 2% BSA in PBS was added, and incubated at room temperature for I
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-hr. Following incubation., plates were washed with PBS, 100 III of 1:3000 dilution of
appropriate cytokine secondary antibody (Sigma and Chemicon) in 2% BSA in PBS was
added, and incubated at room temperature for 1 hr. Plates were then washed with PBS.
followed by the addition of 100 III p-NPP disodium hexahydrate (16 mg/ml~ BioworJd.
Dublin., OH) in Glycine Buffer (0.1 M Glycine, 1 mM ZnCh. I mM MgCh. pH 10.4).
ELISA microtiter plates were then incubated (in the dark) at room temperature for 24 hrs
before absorbance at 405 nm was determined using an EL800 Universal Microplate
Reader (Bio-Tek Instruments, Winooski, VT).
3.2.4.6.1. Data analysis
From the raw data collected on the Universal Microplate Reader, the mean and
the standard error of the mean (SEM) were calculated. The mean and standard error of
the mean were plotted against standard curves allowing the quantification of cytokine
production. Graphics were produced using SigmaPlot software.
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CHAPTER IV
RESULTS AND DISCUSSION
Experiments were designed to answer the following questions. First. why have
only three (HI, H2, and H3) out of ftfteen HA subtypes been circulating in humans?
Second, is the HA responsible for viral pathogenicity? If so. what is the mechanism? I
hypothesized that for a more pathogenic influenza virus. a higher level of cytokines will
be induced in this in vitro lymphocyte model. I postulate that, since HA is an important
factor in pathogenicity. By using different influenza viruses, the role of the HA is
pathogenicity can be studied.
Most studies on cytokines are involved in testing their ability to elicit an
immune response. However, few have investigated the intrinsic stimulation of cytokines
by influenza viruses. Therefore, I need to determine the parameters for the RT-PCR and
ELISA. To optimize the RT-PCR method, I used an adult human peripheral blood
lymphocytes (PBL).
4.1. Pilot study using human adult peripheral blood lymphocytes (POL)
Human adult PBl were used to set the parameters for the RT-PCR test and to test
the'mitogenic properties of influenza virus HA, RT-PCR was used to assay for the
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transcriptional levels ofIFN-y, IL-2, IL-lO, and IL-12. Results of these experiments are
presented in Fig. 4-IA and Fig. 4-1B.
A)
Ml 1 2 34M2
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Fig. 4-1A. Production of cytokines using cytokine-specific primers by non- stimulated buman adult
PBL RNA was isolated, subjected to RT-PCR., and electrophoresed in 1.5% agarose gel (100 V for 30
min). MI = l-Kb DNA ladder; M2 = 100 bp DNA ladder; lane 1 = IFN-y; lane 2 = IL-12; lane 3 = IL-2;
lane 4 = IL-IO.
Fig. 4-1B. IL-2 production by human adult PBL 12 brs post virus stimulation using IL-2 specific
primers. RNA was isolated 12 hrs after infection, subjected to RT-PCR and electrophoresed in 1.5%
agarose gel (100 V for 30 min). Ml = I-Kb DNA ladder; M2 = 100 bp DNA ladder; lane I =
AJJapan/305/57 (H2N2); lane 2 = AJAichi/2/68 (H3N2); lane 3 = AlEqlKentucky/l/98 (H3N8); lane 4 =
NEg/Prague/56 (H7N7); and lane 5 = PBS.
In Fig. 4-1A, production of either Thl or Th2 type of cytokines by the non-
stimulated human adult PBL was not detected. However, 12 hrs after stimulation, as
shown in Fig. 4-1B, induction ofIL-2 transcript (indicated by the 382 bp fragment) was
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present when the human PBL were stimulated by A/Japan/305/57 (H2N2), AiAichi/2/68
(H3N2), A1EqlKentucky/I/98 (H3N8), and A1Eq/Prague/56 (H7N7) influenza viruses. In
contrast, cells pulsed with PBS alone did not produce IL-2 indicating that expression of
IL-2 is a result of virus stimulation. Therefore, influenza virus HA has a mitogen-like
property. and it can induce cytokine production in this PBL system.
However, I was unable to determine if the production of cytokines by this adult
human PBL was a result of previous exposure to influenza viruses. Most adults have
either been infected or have been vaccinated. This induction of IL-2 is possibly a recall
response. However, it is known that less than 0.1 % of all lymphocytic cells are memory
cells [95]. Furthermore, most humans do not have memory towards equine H7N7
influenza virus or the human H2N2 subtype. Therefore. the level of cytokines detected
was higher than expected if it resulted from memory cell re-activation. Therefore. I
concluded that this induction of cytokines was an intrinsic response due to influenza
virus. To ensure that there was no memory cell response involved, I utilized an equine
system in which I was using naIve PBI..
4.2. Naive equine peripheral blood lymphocytes (POL)
Equine PBL, obtained from yearlings. were tested for serum crossreactivity
towards equine influenza viruses. Absence of recall response allowed me to determine
the parameters for cytokine gene transcription. and to determine the types of cytokines
induced. Results of these experiments are presented in Fig.4-2A and Fig. 4-2B.
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Fig. 4-2A. Induction of cytokioes by eqoine-l and eqwoe-l influenza viruses in equine naive PHI...
RNA was extracted 3 hrs after infection, subjected to RT-PCR and electrophoresed in 1.5% agarose gel
(100 V for 30 min). MI = I-Kb DNA ladder; M2 = 100 bp DNA ladder. Lanes 1, 4, 7, 1.0 =
AlEqlKentuckylI/98 influenza virus; lanes 2, 5, S, II = AlEq/Praguel56 influenza virus; lanes 3, 6, 9, 12 =
PBS.
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Fig. ~2B. Induction of cytokines by equine-l and equine-2 influenza viruses in equine naive PBL
RNA was extracted 12 hrs after infection, subjected to RT-PCR and electrophoresed in 1.5% agarose gel
(100 V for 30 min). Ml = I-Kb DNA ladder; M2 = 100 bp DNA ladder. Lanes I, 4, 7, 10 =
NEq/Kentucky/l/98 influenza virus; lanes 2, 5,8, II = NEq/Praguel56 influenza virus; lanes 3, 6, 9, 12 =
PBS.
Three hours after infection naIve equine PBL produced both Thl and Th2 type
cytokines as shown in Fig. 4-2A. Production ofIL-12 (475 bp fragment), IL-2 (382 bp
fragment) and IL-IO (495 bp fragment) was observed. IFN-y was induced in very low
quantities, and only after infection with equine-2 (H3N8) influenza virus. Transcription
of IL-12, IL-IO, and IL-2 was highly increased following infection with the more
pathogenic A/EqlKentucky/l /98 (H3N8) influenza virus. The less pathogenic
A/Eq/Prague/56 (H7N7) influenza virus, however induced a lower level of cytokines.
Twelve hours after infection (Fig. 4-2B) equine-naive PBL showed a decreased
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ThI-type cytokine production., while Th2-type cytokine production remained constant.
Production of IFN-y and IL-2 was not detected by RT-PCR. Production of IL-12 is
decreased when compared to 3 hrs after infection and attained the same level with either
of the two equine influenza viruses. Induction ofIL-lO (495 bp fragments) was increased
when compared to 3 hrs samples. However, the difference between the two equine
influenza viruses was not observed.
Production of both Thl and Th2 cytokines was observed as early as 3 hrs
following infection, and continued on at 12 hrs. This pattern of cytokine expression was
attributed to the mitogen-like properties of influenza virus, or more likely due to the
surface HA. Differences seen in cytokine induction between 3 and 12 hrs post infection
suggested that kinetics of Thl and Th2 type cytokine differ. It is probable that Th1 type
cytokine production peaked before the 12 hrs. However, the decrease in Th1 cytokine
production was possibly due to regulation by the induced IL-l O.
The equine influenza viruses used. equine-2 A/EqlKentuckyll/98 (H3N8) and
equine-l A/EqlPrague/56 (H7N7). have different pathogenicity. Clinical symptoms
caused by equine-2 influenza virus are more severe than by the equine-l influenza virus.
Therefore, I attributed the difference in cytokine induction to difference in pathogenicity
of these two viruses.
Detection of cytokine gene expression by RT-peR was important, however a
quantifiable assay, such as ELISA. is needed to quantify the true induction of cytokines.
Lack of crossreactivity between human cytokine antibodies and equine-produced
cytokines prevented me from performing such a quantifiable analysis on naIve equine
PBL. Most equine cytokine-specific antibodies are not available, therefore I switched to
51
Jurkat human T cell line as human cytokine-specific antibodies are available
conunercially.
4.3. Jurkat human T cell line
Jurkat cells are a pseudodiploid human T cell line. They are not memory cells.
Jurkat cells, if properly stimulated, produce a variety of cytokines [13. 62. 64. 77].
Therefore, Jurkat T cells represent a suitable model for studying in vitro cytokine
induction.
Jurkat cells were cultured in RPMl with 10% (w/v) FBS and incubated at 37°C
and 5.0 % CO2 Cells were diluted to 2.5 x 106 cells/ml and pulsed for 4 hrs with 50 III (1
HA unit/2.5x106 cells) of contro~ BlLee/40, NEqlPrague/56 (H7N7).
AlEq/Kentucky/l/98 (H3N8), NEqIKentucky/1/97 (H3N8), AlEq/Saskatoon/1/90
(H3N8), NEqlMiami/I/63 (H3N8), AlPanama/99 (IDN2), A/Aichi/2/68 (H3N2),
A/Japan/305/57 (H2N2), A/swinelNew Jersey/11176 (HI N I). AlPuerto Rico/8/34
(HI NI) and mitogen. Four hours after infection, virus-containing supernatant fluids were
removed. and 1.0 ml of fresh, virus-free, optimum OptiMEM I medium was added to the
cells. They were incubated at 37°C and 5.0 % CO2 for 24 hrs before the supernatant
fluids were collected and assayed by ELISA.
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4.3.1. Thl type cytokines
4.3. J. J. Interferon-y (lFN-y)
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Fig. 4-3A. Production of IFN-y by Jurkat T cells 24 brs post-infection witb UV-inactivated influenza
viruses. Error bars represent the standard error of the mean for each virus tested.
As seen in Fig. 4-3A, influenza viruses and the positive control induced IFN-y,
while the negative control did not induce detectable amounts of this cytokine. Influenza
viruses induced the following amounts of IFN-y: BlLee/40 (0.77 +/- 0.03 ng/ml),
AfEqlPrague/56 (lI7N7) (0.92 +/- 0.03 ng/ml), AfEqiKentucky/l/98 (H3N8) (1.03 +/-
0.04 ng/ml), AfEqiKentucky/l/97 (H3N8) (0.92 +/- 0.02 ng/ml), AfEq/Saskatoon/l/90
(H3N8) (1.03 +/- 0.03 ng/ml), AfEqlMiami/l/63 (ffiN8) (0.97 +/- 0.03 ng/ml),
A/Panama/99 (H3N2) (0.85 +/- 0.02 ng/ml), AIAichi/2/68 (H3N2) (0.95 +/- 0.04 ng/ml),
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A1Japan/305/57 (H2N2) (0.85 +/- 0.02 ng/ml), A1swinelNew Jersey/l 1/76 (HINI) (0.99
+/- 0.05 nglml), and A/Puerto Rico/8/34 (HINi) (1.0 +/- 0.03 nglml). Mitogen (positive
control) induced 0.97 +/- 0.05 nglml ofIFN-y.
Influenza A viruses induced higher levels of IFN-y than did influenza B virus.
This may be associated with the difference in their surface HA and clinical pathogenicity.
Influenza A virus subtypes, HI and ID, with the exception of A1Panama/99 (H3N2)
induced higher amounts ofIFN-y than the A/Japan/305/57 (H2N2) virus.
4.3.1.2. Interleu/dn-2 (IL-2)
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Fig. 4-38. Production of JL.2 by Jurkat T cells 24 brs post-infection witb UV-inactivated influenza
viruses. Error bars represent the standard error of the mean for each virus tested.
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IL-2 was induced by all influenza viruses (Fig. 4-3B). however it was also
produced by the mock-infected ceUs (16.4 +/- 0.12 ng/rnl). Induction ofIL-2 by mock-
infected cells may have resulted from cell stress and cell death. and it was much lower
than induced by influenza A viruses. Induction of IL-2 by influenza B virus (18.4 +/-
0.77 ng/rnl) is different from mock-infected cells. However. whether it is biologically
important remains to be determined.
Influenza A viruses induced the following quantities of IL-2: AfEqlPrague/56
0(H7N7) (20.70 +/- 0.72 ng/rnl), AJEq/Kentllckyll /98 (H3N8) (20.80 +/- 0.77 ng/mI).
AfEqlKentuckyll/97 (H3N8) (21.20 +/- 0.68 ng/ml), AJEq/Saskatoon/1/90 (H3N8)
(20.70 +/- 0.77 ng/rnl), AJEqIMiamilll63 (H3N8) (21.50 +/- 0.58 ng/rnl). AlPanama/99
(H3N2) (18.7 +/- 0.17 ng/rnl), AIAichi/2/68 (H3N2) (22.2 +/- 1.20 ng/ml).
A/Japan/305/57 (H2N2) (21.7 +/- 0.54 ng/rnl), AlswinelNew Jerseyll1176 (HIN1) (21.9
+/- 0.85 ng/ml), and AlPuerto Rico/8/34 (H1Nl) (23.2 +/- 0.95 ng/rnl).
Influenza A viruses. with the exception of AlPanama/99. induced higher levels of
IL-2 than did influenza B virus. IL-2 was induced in similar amounts by all influenza A
viruses. This high level may be due to an accumulation of this cytokine. as it was
induced early. In addition, IL-2, is a proliferative cytokine needed for cell activation,
therefore it is not surprising that it is secreted in high amounts during an infection.
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4.3.2. Th2 type cytokines
4.3.2.1. Interleukin-4 (IL-4)
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Fig. 4-3C. Production of Ilr4 by Jurkat T cells 24 brs post-infection witb UV-inactivated influenza
viruses. Error bars represent the standard error of the mean for each viruses tested.
As shown in Fig. 4-3C, influenza B virus (BlLee/40) induced minimal quantities
(0.66 +/- 0.02 ng/ml) ofIL-4. Influenza A viruses induced high amounts oflL-4 with the
following quantities: A1Eq/Prague/56 (H7N7) (8.10 +/- 0.13 ng/ml), A1EqlKentucky/1I98
(H3N8) (14.80 +/- 0.42 ng/ml), A1Eq/Kentucky/l/97 (H3N8) (14.60 +/- 0.31 ng/ml),
A1Eq/Saskatoon/1I90 (H3N8) (23.40 +/- 0.63 ng/ml), A1EqlMiami/1I63 (H3N8) (17.30
+/- 0.47 ng/ml), A1Panama/99 (H3N2) (6.75 +/- 0.06 ng/ml), AlAichi/2/68 (H3N2) (27.0
+/- 2.97 ng/ml), A/Japan/305/57 (H2N2) (54.0 +/- 10.26 ng/ml), AlswinelNew
Jerseyl11176 (HINl) (42.20 +/- 5.90 ng/ml), and AJPuerto Rico/8/34 (HINl) (69.10 +/-
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18.7 nglml). The high induction ofIL-4 was also observed from mitogen stimulated cells
(53.10 +/- 10.6 nglml).
IL-4 was induced in higher levels by influenza A viruses than by the influenza B
VIrUS. Among influenza A viruses H2 and HI subtypes induced higher levels of IL-4
than did H3 and H7 subtypes. Difference in virus surface HA is potentially responsible
for the observed variations. Among equine influenza A viruses, equine-2 (H3N8)
influenza virus induced more IL-4 than did equine-I (H7N7) influenza virus (Fig. 4-3C).
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4.3.2.2. 1nterleukin-6 (1L-6)
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Fig. 4-3D. Production of Il.r6 by Jurkat T cells 24 hrs post-infection with UV-inactivated influenza
viruses. Error bars represent the standard error of the mean for each virus tested.
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-IL-6 was produced by both, mock-infected and influenza virus infected Jurkat T
cells (Fig. 4-3D). Mock-infected ceUs, possibly due to cell stress and cell death.
produced 8.7 +/- 0.09 ng/ml ofIL-6. Influenza B virus (BlLee/40) induced 9.6 +/- 0.22
ng/ml of IL-6, different from the mock-infected cells, however biological importance
requires further testing.
Influenza A viruses induced the following quantities of IL-6: AfEqlPrague/56
(H7N7) (9.60 +/- 0.22 nglml), AfEqlKentuckyll/98 (H3N8) (12.0 +/- 0.36 ng/ml).
AlEqlKentuckyll/97 (H3N8) (12.60 +/- 0.26 ng/ml), AJEq/Saskatoon/1I90 (H3N8) (13.0
+/- 0.39 ng/ml), AlEqIMiamil1l63 (H3N8) (13.0 +/- 0.45 nglml), NPanama/99 (H3N2)
(10.90 +/- 0.19 ng/ml), AJAichi/2/68 (H3N2) (13.0 +/- 0.26 ng/ml). AJJapan/305/57
(H2N2) (1l.0 +/- 0.25 ng/ml), AJswinelNew Jersey/1l176 (HINI) (12.20 +/- 0.18 ng/mll.
and NPuerto Rico/8/34 (HINl) (12.80 +/- 0.47 ng/ml) ofIL-6. The importance of IL-6
induction is supported with similar induction by mitogen stimulated Jurkat T cells (12.40
+/- 0.37 ng/ml).
Influenza A viruses induced more IL-6 than influenza B viruses. Again, influenza
virus subtypes. HI, H3, and H7, induced higher levels oflL-6 when compared to the H2
subtype.
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4.3.2.3. lnterleuldn-IO (IL-JO)
Jurk.thum.n T cells
Fig.4-3E. Production of IL-IO by Jurkat T ceUs 24 hrs post-infection with UV-inaetivated influenza
viruses. Error bars represent the standard error of the mean for each viruses tested.
Only influenza A viruses induced IL-IO (Fig. 4-3E): A/EqIPrague/56 (H7N7)
(0.07 +1- 0.01 nglrnl), AlEqlKentucky/l/98 (H3N8) (0.37 +/- 0.02 nglml),
AlEq/Kentucky/l/97 (H3N8) (0.21 +/- 0.02 ng/ml), AlEq/Saskatoon/1/90 (H3N8) (0.50
+1- 0.08 nglml), AlEqlMiami/I/63 (H3N8) (0.22 +/- 0.02 nglrnl), A1Panama/99 (H3N2)
(0.49 +1- 0.04 nglml), AIAichi/2/68 (H3N2) (0.22 +1- 0.02 nglml), AlJapan/305/57
(H2N2) (0.14 +/- 0.02 nglml), AlswinelNew Jersey/ll176 (H IN I) (0.24 +/- 0.02 ng/ml),
and A1Puerto Rico/8/34 (HINI) (0.31 +1- 0.04 nglmI). Mitogen (positive control)
induced 0.25 +/- 0.04 ngimI ofIL-I O.
Among type A influenza viruses, H3 and HI subtypes induced more IL-IO than
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did H2 subtype. This pattern was also seen with IFN-y and IL-6. Comparing equine
influenza A viruses, equine-2 (H3N8) induced higher level of IL-l 0 than did equine-I
(H7N7) subtype. HI viruses induced similar amounts of IL-I O. while H3 iruses were
split into two groups. The fIrst group, containing AlEqlKentucky/98, AlEq/Saskatoon/90
and AfPanama/99, induced a high level of IL-IO. These viruses are relatively new in
circulation. The recent evolutionary changes, since 1990. in H3 subtypes may have
resulted in higher induction oflL-I O.
The advantage of using Jurkat T cell line makes it an efficient and economic
choice for an in vitro model for cytokine induction. However, it is consisted of one cell
type. Influenza virus infection in vivo is associated with several cell populations.
Therefore. I decided to use the human umbilical cord blood lymphocytes. The presence
of heterologous cell populations, absence of memory cells, make usage of umbilical cord
blood lymphocytes a more proper model for the analysis.
4.4. Human umbilical cord blood
The absence of recall immunity, and being a mixed population of cells. composed
of both Band T lymphocytes, phagocytic cells, and auxilary cells, allowed me to test the
true intrinsic induction of cytokines as a result of similarity to an in vivo setting.
Lymphocytic cells obtained from human umbilical cord blood sample were
diluted to 2.5 x 106 cells/ml, and pulsed for 4 hrs with 50 I..d (1 HA unit/2.5xI06 cells) and
500 JlI (10 HA units/2.5xI06 cells) of control, B/Lee/40. A/Eq/Kentuckyll/98 (H3N8).
AlPanama/99 (H3N2), A/Aichi/2/68 (H3N2), A/Japan/305/57 (H2N2), A/swinelNew
Jerseylll176 (HINI), A/Puerto Rico/8/34 (HINl) and mitogen. Four hours after pulsing.
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virus-containing supernatant fluids were removed. One milliliter of fresh, virus-free,
optimum OptiMEM I medium was added, and cells were incubated at 37 °C and 5.0%
C02 for 24 hrs before the supernatant fluids were collected and assayed by ELISA.
4.4.1. Th1 type cytokines
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Fig. 4-4A. Production of IFN-y by human umbilical cord Iympbocytes 24 brs post infection with UV-
inactivated inOuenza viruses. Error bars represent the standard error of the mean for each virus tested.
Only influenza A viruses induced IFN-y regardless of virus concentration (Fig. 4-
4A). One HA unit of influenza A viruses induced the following quantities of IFN-y:
A/Eq!Kentuckyll/98 (H3N8) (0.58 +/- 0.01 nglml), NPanama/99 (H3N2) (0.45 +/- 0.02
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nglml), A/Aichi/2/68 (H3N2) (2.2 +1- 0.10 nglml). A/swinelNew JerseyllI176 (HI I)
(2.3 +/- O. I0 nglml), A/Puerto Rico/8/34 (HIN 1) (1.03 +/- 0.05 nglrnl), and
A/Japan/305/57 (H2N2) (0.52 +1- 0.01 nglrnl).
Ten HA units of influenza A viruses induced the following quantities of IFN-y:
AlEq/Kentuckyll/98 (H3N8) (2.5 +1- 0.05 ng/ml), AlPanama/99 (H3N2) (0.82 +1- 0.0 I
nglml), A/Aichi/2/68 (H3N2) (2.0 +1- 0.01 nglml), A/swinelNew JerseyllI176 (HINI)
(2.1 +1- 0.02 nglmn, A/Puerto Rico/8/34 (HINl) (1.75 +1- 0.03 ng/ml). and
A/Japan/305/57 (H2N2) (2.13 +/- 0.09 nglml) ofIFN-y.
Strong difference in IFN-y induction between influenza A and influenza B viruses
were observed. Among influenza A viruses, difference in cytokine induction is detected
mainly in experiments using one HA unit of viruses. Subtypes. H3 (AlAichi/68) and HI
induced four times as much IFN-y than did the H2 subtype. The other two H3 subtypes
did not induce as high levels of IFN-y as AIAichi/68. This may be associated with their
attenuated pathogenicity resulting from 30 years ofevolutionary changes.
Similar induction of IFN-y by most influenza A viruses after stimulation with 10
units of influenza viruses, could be associated with high production of IFN-y. or cell
death due to high virus concentration. High induction of IFN-y could have resulted in
over-saturation of ELISA assay. Due to the high production of IFN-y. the pH of the
binding buffer is changed possibly preventing the protein binding to the microtiter plate.
Followed by plate washing, the unbound proteins are washed of( resulting in a lower
detection of true cytokine induction. This is best seen with AIAichi/2/68 (H3N2) and
A/swinelNew Jerseyl11/76 (HINI).
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4.4.1.2. Interleukin-2 (IL-2)
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Fig. 4-4B. Production of 1L-2 by human umbilical cord lymphocytes 24 brs post Infection with UV-
inactivated influenza viruses. Error bars represent the standard error of the mean for each virus tested.
As Fig. 4-4B shows, high quantities of IL-2 were detected. IL-2 was produced by
mock-infected cells (50 ,...1 and 500 ,...1 produced 15.3 +/- 0.153 ng/ml and 15.2 +/- 0.076
ng/ml respectively). Experiments using one HA unit of influenza A viruses indicated
similarity in levels ofIL-2 induction: A/Eq/Kentucky/l/98 (H3N8) (21.9 +/- 0.33 ng/ml),
AlPanama/99 (H3N2) (22.75 +/- 0.66 ng/ml), A/Aichi/2/68 (H3N2) (23.0 +/- 0.44
ng/rol), A/swinelNew Jerseylll/76 (HINl) (25.4 +/- 1.11 ng/ml), AlPuerto Rico/8/34
(HINl) (22.1 +/- 0.26 ng/ml), and A/Japan/305/57 (H2N2) (23.7 +/- 0.55 ng/ml).
Influenza B virus (B/Lee/40), induced 16.2 +/- 0.15 ng/ml. This is more than induced by
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mock-infected cells, however biological importance could not be determined.
Ten HA units of influenza A viruses induced the following quantities of IL-2:
AlEqlKentucky/1I98 (H3N8) (20.1 +/- 0.56 ng/ml), A/Panama/99 (H3N2) (21.4 +/- 0.34
ng/ml), NAichi/2/68 (H3N2) (21.0 +/- 0.19 ng/ml) ofIL-2, NswinelNew Jersey/1l176
(HINl) (29.0 +/- 1.97 ng/ml), A/Puerto Rico/8/34 (HIN}) (26.8 +/- 1.10 ng/ml). and
AlJapan/305/57 (H2N2) (28.2 +/- 1.20 ng/ml).
Higher levels ofIL-2 were induced by the same viruses than the induced levels of
IFN-y. This may be attributed to IL-2's proliferative functions. Infection by influenza B
virus, B/lee/40. in one HA unit or ten HA units showed the ability of this low pathogenic
virus to induce IL-2 production. Despite the lower level ofIL-2 induction by influenza B
virus. induction of other cytokines, such as IL-6, can result in development of very mild
influenza symptoms.
Influenza A viruses induced higher levels of IL-2 than did influenza B virus.
Similar induction of IL-2 among influenza A viruses possibly resulted from early
production of IL-2, resulting in its accumulation. Identical pattern was observed with
influenza A virus stimulated Jurkat T cells. Experiments completed using ten HA units
of viruses showed a similar result if interpreted with possibility that a lower IL-2
detection by H3 subtypes resulted from ELISA over-saturation.
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-4.4.2. Th2 type cytokines
4.4.2.1. Interleukin-4 (lL-4):
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Fig. 4-4C. Production of IL-4 by buman umbilical cord Iympbocytes 24 brs post infection witb UV-
inactivated influenza viruses. Error bars represent the standard error of the mean for each virus tested.
As shown in Fig. 4-4C, one HA unit of influenza viruses induced the following
quantities ofIL-4: BlLee/40 (0.8 +/- 0.15 nglml), AlEqlKentukcy/1I98 (H3N8) (12.7 +/-
0.99 ng/ml), A1Panama/99 (H3N2) (10.5 +/- 0.39 nglml), NAichi/2/68 (H3N2) (18.9 +/-
1.75 ng/ml), NJapan/305/57 (21.0 +/- 2.10 ng/ml), NswinelNew Jersey/1l176 (HINt)
(21.8 +/- 2.30 ng/ml), and A1Puerto Rico/8/34 (19.7 +/- 1.91 ng/ml).
Ten HA units of influenza viruses induced the following amounts of IL-4:
B/Lee/40 (1.9 +/- 0.008 ng/ml), AlEq!Kentucky/1I98 (H3N8) (27.5 +/- 0.44 ng/ml),
AlPanama/99 (H3N2) (22.7 +/- 0.27 nglml), N Aichi/68 (H3N2) (25.8 +/- 0.75 ng/ml),
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A/Japan/305/57 (H2N2) (35.5 +/- 1.81 ng/ml), A/swinefNew Jersey/1l176 (HINl) and
(36.7 +/- 1.25 ng/ml), and AlPuerto Rico/8/34 (27.8 +/- 0.361 ng/ml).
Differences observed between influenza A and influenza B viruses suggests
biological importance. At ten HA units of all influenza viruses, including type B, a 2-
fold increase of IL-4 is observed when compared to one HA unit of influenza viruses.
Therefore, I conclude that cells stimulated with higher concentration of influenza viruses
induce higher amounts of cytokines. IL-4 was induced in similar amounts among
influenza A viruses.
4.4.2.2. Interleuldn-6 (IL-6)
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Fig.4-4D. Production of lL-6 by human umbilical cord lymphocytes 24 hrs post infection with UV-
inactivated influenza viruses. Error bars represent the standard error of tile mean for each virus tested.
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As shown in Fig. 4-4D, IL-6 was also produced by mock-infected cells. Fifty
microliters of allantoic fluid induced 10.9 +/- 0.14 ng/ml, while 500 III of allantoic fluid
induced 11.4 +/- 0.33 ng/ml. Similar data was obtained with the lurkat T cell line. On~
HA unit of influenza viruses induced the following quantities ofIL-6: BlLee/40 (l 1.8 +/-
O. 15 ng/ml), AlEqlKentucky/1I98 (H3N8) (15.0 +/- 0.42 ng/ml). AlPanama/99 (H3 2)
(14.6 +/- 0.35 ng/ml), and NAichi/2/68 (H3N2) (17.2 +/- 0.38 ng/ml). NJapan/305/57
(14.6 +/- 0.26 ng/ml), NswinelNew Jerseyl11/76 (HINI) (16.5 +/- 0.40 ng/mn and
AlPuerto Rico/8/34 (HINl) (16.6 +/- 0.96 ng/ml).
Ten HA units of influenza viruses showed similar induction: BlLee/40 (12.2 +/-
0.73 ng/ml), AlEq/Kentucky/1/98 (H3N8) (17.8 +/- 0.71 ng/ml), A1Panama/99 (H3N2)
(14.5 +/- 0.29 ng/ml), NAichi/2/68 (H3N2) (l7.7 +/- 1.26 ng/ml). NJapan/305/57
(H2N2) (l5.4 +/- 0.38 ng/ml), NswinelNew Jersey/I 1176 (18.8 +/- 0.30 ng/ml), and
AlPuerto Rico/8/34 (HINl) (16.0 +/- 0.45 ng/ml).
Interleukin-6 was induced in high quantities following infection with influenza
viruses. Influenza B virus induced lower levels of IL-6 than did influenza A viruse .
Suhtypes. H3 NAichi/68, and both HI viruses induced more IL-6 than did the H2
subtype. Similar pattern was obtained with IFN-y induction. Ten HA units of influenza
viruses induced approximately two times as much IL-6 than did the mock-infected cells.
Lower induction of IL-6 detected for AlPanama/99 (H3N2) and AlPuerto Rico/8/34
(H IN 1) with ten HA units concentration could be attributed to ELISA over-saturation.
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4.4.2.3. Interleu/dn-IO (IL-IO)
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Fig. 4-4E. Production of IL-IO by buman umbilical cord lymphocytes 24 brs post infection witb UV-
inactivated influenza viruses. Error bars represent the standard error of the mean for each virus tested.
As shown in Fig. 4-4E, experiments conducted using one unit of influenza viruses
showed induction of IL-l 0 in the following amounts: BlLee/40 (0.017 +/- 0.001 ng/ml),
AlEq/Kentucky/l/98 (H3N8) (0.45 +/- 0.04 ng/ml), AlPanama/99 (H3N2) (0.39 +/- 0.03
nglml), AIAichi/2/68 (H3N2) (0.33 +/- 0.03 nglml), AlJapan/305/57 (H2N2) (0.153 +/-
0.01 ng/ml), Alswine/New Jersey/I 1176 (0.33 +/- 0.03 nglml) and AlPuerto Rico/8/34
(0.11 +/- 0.01 ng/ml).
Ten HA units of influenza VlfUses induced the following levels of IL-lO:
B/Lee/40 (0.007 +/- 0.0001 ng/ml), AlEqlKentucky/l/98 (H3N8) (0.434 +/- 0.06 nglml),
AlPanama/99 (H3N2) (0.276 +/- 0.01 nglml), AlAichi/2/68 (H3N2) (0.352 +/- 0.03
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ng/ml), AlJapan/305/57 (H2N2) (0.223 +/- 0.01 ng/ml), AlswinelNew Jersey/1ll76
(HlNl) (0.382 +/- 0.02 ng/ml), and AlPuerto Rico/8/34 (HINt) (0.50 +/- 0.02 ng/ml).
Interleukin-lO was induced in small but important quantities after influenza virus
infection if compared to similar induction by mitogen stimulated cells. Influenza A
viruses induced a higher level of IL-l 0 than did influenza B virus. Among influenza A
viruses, subtypes H3 and HI induced a two-fold more IL-IO than did the H2 subtype.
Similar patterns were observed with IFN-y and IL-6 induction. Therefore, the surface
hemagglutinin of subtypes H3 and HI may be higher inducers of both Thl and Th2 type
cytokines.
4.5. Summary
According to my data, a more pathogenic influenza A virus induced a higher level
of cy!okines than did a less pathogenic influenza B virus. Furthermore, it appears that the
hemagglutinin plays an important role in cytokine induction, by comparing H3N2 and
H3N8 viruses. Even-though, they are different in their NA subtypes. they elicit a similar
level of cytokines. The more divergent the viruses are, the higher the difference in the
l~vels of cytokine induction. Influenza A and influenza B viruses surface HAl are 31.5%
homologous on the amino acid level, while some of the influenza A viruses are as
homologous as 98.4% on the amino acid level. Furthermore. A/EqfPrague/56 (H7N7)
shares the closest homology to the influenza B virus, and it induces the lowest levels of
cytokines among any influenza A virus tested. A summary of influenza virus HA 1
percent homology is shown in table 4-1.
69
TABLE 4-1
HAl PERCENT HOMOLOGY
2 3 4 5 6 7 8 9 10
1 65.7 58.5 62.5 65.0 64.9 64.8 57.1 56.4
2 71.6 60.3 62.2 61.8 61.8 56.4 53
3 41.6 42./J 61.4 62.0 61.9 61.9 56.1 55.1
4 40.1 35.4 40.' 76.5 76.4 76.1 56.9 55.0
5 31.4 35.1 3'.2 91.4 60.7
6 40.0 35.1 35.' 97.7 61.8
7 40.4 35.0 36.3 61.9
8 40.4 35.1 36.7 61.8
9 32.4 31.5 32.2
10 27.6 21.0 27.4
The upper half, white background, represents nucleotide homology in HAl portion of virus surface HA.
The lower half, gray background, represents amino acid homology in HAl portion of virus surface HA.
Influenza viruses used in this study are compared with the exception of AlPanama/99 (IDN2) virus, whose
HA I sequence is not available. The influenza viruses are ordered nwnerically; 1) NPuerto Ricol8/34
(HINI), 2) A/swinelNew Jersey/ll/76 (HINI), 3) NJapan/305/57 (H2N2), 4) NAichil2/68 (H3N2), 5)
NEq/Miamilll63 (IDN8), 6) NEq/Saskatoon/1l90 (IDN8), 7) NEq/Kentucky/l/97 (H3N8), 8)
NEqfKentucky/l/98 (H3N8), 9) NEq/PragueJ56 (H7N7), and 10) SfLee/40.
One exception to this general observation, is that H3 and HI subtypes are more
divergent from each other than they are from the H2 subtype. Despite this difference, H3
and HI induced more cytokines than did the H2 virus. Therefore, it is not the overall
homology among HA proteins that detennines their inductive capacities, but rather the
specific amino acid sequences of the surface protein may determine the level of cytokine
induction.
A high mutation rate of influenza viruses could be associated with difference or
similarity in cytokine induction among different subtypes of influenza viruses. For
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example, similar induction of IL-6 by A/Japan/57 (H2N2) and AlEq/Miami/63 was
determined. However, the other H3 subtypes induced higher amounts than of IL-6 than
did H2 subtype. This may have resulted from the evolutionary changes in H3 influenza
virus subtypes since 1963. Furthermore, among human influenza virus subtypes H3.
A/Panama/99 induced less IFN-y, IL-4, and IL-6, than did its ancestor A/Aichi/2/68. On
the contrary, it induced more IL-IO. Long duration and circulation of the human H3
subtypes, as well as thirty-one years of antigenic drift from N Aichi/2/68 (H3N2) to
A/Panama/99 (H3N2) may be responsible for the appearance of a less pathogenic
influenza virus. Exact factors are not clear. A possible explanation is that influenza virus
subtype H3, due to long evolution in humans resulted in a "co-adaptation" of this
influenza virus subtype with the host. Therefore, the new human H3 influenza virus
subtypes, such as A/Panama/99, are possibly less pathogenic, hence inducing a weaker
immune response and a lower cytokine induction.
Reduced immune response would most likely result in the humoral immune
response development. Therefore, the Th2 types of cytokines would be primarily
induced. As seen with our data, two out of three Th2 type of c)10kines are secreted in
high amounts, especially the IL-4. As shown by Sharma et. al P8]. and Moran el. at.
[60], high induction of IL-4 impedes virus clearance by activation of humoral immune
response. Therefore, it is possible that co-evolution between influenza virus and its host
may result in "co-adaptation" by a higher induction IL-4.
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CHAPTER V
CONCLUSIONS
The success of influenza viruses is attributed to their capacity to mutate rapidly.
Current circulating viruses, especially the JU subtypes, have been shown to mutate at
high rates [7]. Pathogenicity and virulence has been attributed to virus evolution.
antigenic drift allows the virus to ·'re-infect" an immune individual. Using phylogenetic
analysis Bush el. al. [7], and Hillis [35], have shown that, by using specific criteria.
evolution ofH3N2 virus may be "predicted". However, the criteria used in their studies
is not suitable to test any potentially pathogenic virus for humans. This study is a frrst
attempt to analyze whether there is a correlation between cytokine induction and
pathogenicity of influenza viruses.
5.1. Conclusions
Adult human PBL must be stimulated to produce cytokines. Following infection.
the mitogen-like properties of the influenza virus HA protein induced simultaneous
release of Thl and Th2 cytokines. Furthermore, influenza A viruses induced higher
levels ofIFN-y, IL-2, IL-4, IL-6, and IL-IO than did influenza B virus. Among influenza
A viruses: the equine-2 (H3N8) subtypes induced higher levels of IFN-y, IL-4, IL-6, IL-
10 and IL-12 than did equine-I (H7N7) subtype. Furthermore. H3 and H I influenza
virus subtypes were found to be higher inducers of IFN-y, IL-6, and IL-IO than were the
H2 or H7 influenza virus subtypes. Therefore. I concluded that more pathogenic
influenza viruses induce higher levels of cytokines than the less pathogenic viruses.
Furthermore, I concluded that the influenza virus hemagglutinin plays a major role 10
cytokine induction and in pathogenicity.
5.1.1. Concluding remarks
In vitro testing of human adult PBL. equine naive PBL, the human Jurkat T cells
and human nai've umbilical cord blood showed similar patterns in both the types and
levels of cytokines induced following influenza virus infection. Both types (Thl and
Th2) of cytokines are simultaneously induced. This is in agreement with other studies.
that reported simultaneous induction of Th I and Th2 cytokines by influenza virus
infection in vivo [18, 39, 75]. Therefore. r suggest that in vitro testing of human
umbilical cord blood lymphocytes or Jurkat T cell-line for cytokine induction is a good
model to correlate to in vivo infections.
5.2. Significance
The ability to test cytokine induction with a new influenza virus could lead to
prediction of its pathogenicity and its pandemic potential. Screening of newly isolated
influenza viruses can be done along with current antigenic analyses. This could help in
the development of a better vaccine. A new immunization technique. such as DNA
vaccines, capable of eliciting persistent and longer-lasting humoral and cell-mediated
immune response to a variety of viral antigens [71. 92] can be developmed. Furthermore.
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a similar approach could be used to determine pathogenicity of pathogens other than
influenza, resulting in prevention of the corresponding diseases.
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